A comparison of results for a given patient during anti-tumour therapy with regard to salivary IL-2 showed significant differences between study 2 and study 3 (Wilcoxon signed-rank test; Z = 2.173; p = 0.0297). This evidence concerns the gene IL2 and neoplasm.